A growing body of clinical and experimental evidence shows that neurocognitive dysfunction is a fundamental -- yet frequently ignored or misidentified -- component of bipolar disorder. The first comprehensive book of its kind, Cognitive Dysfunction in Bipolar Disorder: A Guide for Clinicians compiles the latest data in neuropsychology, neuroimaging, neurogenetics, and functional outcomes research to enable clinicians to more effectively utilize pharmacological and psychotherapeutic techniques in their treatment of bipolar disorder.

This volume outlines and demystifies current knowledge about neuropsychological functioning in bipolar disorder in a reader-friendly, easy-to-understand guide for practitioners. Its 12 chapters, written by 23 internationally-renowned expert contributors, examine such topics as attentional and executive functioning, neuroimaging and genetic correlates of cognitive functioning, pharmacological strategies, bipolar disorder in pediatric patients, and cognition across the life span.

The book also comes with the added benefit of • A review of neurocognitive domains, examples of their operation in everyday life, the neuroanatomical regions with which they are associated, and common tests used to assess their function• Summarized data from large-scale clinical trials, including the National Institute of Mental Health Antipsychotic Trials of Intervention Effectiveness (CATIE) study• Take-home points at the end of each chapter summarizing main concepts and "clinical pearls"• Case studies and illustrative examples depicting the application of specific neurocognitive principles

Using relevant applications from cognitive neuroscience, Cognitive Dysfunction in Bipolar Disorder provides clinicians with a comprehensive overview of astounding breakthroughs in the assessment and treatment of patients with bipolar disorder. It plows new ground in the mental health industry, correcting distortions and laying the foundation for future clinical research in this rapidly expanding field.

Information about new psychotropic drugs, a summary of advances in knowledge about identifiable risk factors for adverse effects, and updated recommendations on viable "antidote" management strategies -- including novel pharmacotherapies for tardive dyskinesia and newer agents for weight loss -- are among the features of this new, second edition of Managing the Side Effects of Psychotropic Medications.

Where other psychopharmacology textbooks -- and, indeed, most internships and residencies in psychiatry -- lack a solid basis in primary care medicine, this guide bridges that educational gap, offering a thorough examination of all the effects of taking a psychotropic drug as well practical clinical advice on how to manage complications that arise.

The book is divided into three parts: The first deals with global issues that affect the assessment and formulation of possible adverse effects, as well as with pertinent concepts related to basic pharmacology, physiology, and medical monitoring. The second part presents information organized by individual organ systems or specific medical circumstances. The final part focuses on summary recommendations covering all the material presented in the book and is followed by helpful appendixes and self-assessment questions and resources for practitioners.

This new edition includes: • Updated summaries about what psychiatrists should know regarding drug-drug interactions, iatrogenic cardiac arrhythmias, drug pressor effects and orthostatic hypotension, and drug rashes; as well as updated discussions on avoiding lithium nephrotoxicity, handling adverse effect emergencies, and understanding new FDA classifications about drug safety during pregnancy• An expanded discussion on the strengths and limitations of pharmacogenetic testing to predict adverse drug effects, as well as information about new treatments for sexual dysfunction, sleep disturbances, cognitive complaints, and other maladies• Revised summary tables to aid rapid assessment and management• An expanded section on supplemental resources• An updated and expanded self-assessment section with more key questions

Busy clinicians will find in Managing the Side Effects of Psychotropic Medications an accessible reference that provides both scientific and scholarly discussion of the consequences of drug therapies they may prescribe (or avoid), the range of available strategies to effectively manage adverse effects, and the scientific and practical implications of their treatment decisions.

Aujourd'hui, la polypharmacologie est un outil majeur pour le traitement des patients souffrant de formes graves et chroniques de troubles de l'humeur, d'anxi�t�, de psychose ou de troubles du comportement.

Dans l'esprit des travaux et �crits de Stephen M. Stahl, cet ouvrage offre une vue d'ensemble novatrice sur les connaissances en psychopharmacologie et les strat�gies de prises de d�cision, en int�grant les r�sultats d'essais fond�s sur les preuves aux donn�es de la clinique, avec des exemples et des situations cliniques r�elles. Il aborde la mani�re dont les prescripteurs peuvent mettre en place une � psychopharmacologie sur mesure �, adapt�e aux besoins sp�cifiques de chaque patient, en conservant l'approche et l'�tat d'esprit d'un praticien.

Quelle que soit leur exp�rience, les professionnels pourront ainsi affiner et am�liorer leurs prescriptions et leurs prises en charge, en ciblant les manifestations des circuits neuronaux dysfonctionnels et les dimensions psychopathologiques, au-del� des diagnostics psychiatriques conventionnels.

Pr�sent� sous une forme dynamique, pratique et en couleurs, avec des tableaux de synth�se, des encadr�s et des vignettes cliniques concr�tes, cet ouvrage est un guide pr�cieux d'aide � la d�cision pour tous les praticiens qui prescrivent des psychotropes.

Joseph F. GoldbergProfesseur de psychiatrie clinique,Icahn School of Medicine at Mount Sinai, New York

Stephen M. StahlProfesseur de psychiatrie et de neurologie,University of California Riverside and University of California San Diego

Marc-Antoine Crocq (traducteur)Psychiatre,Maison des adolescents du Haut-Rhin, CAMUHA,Universit� de Haute-Alsace, Mulhouse

A growing body of clinical and experimental evidence shows that neurocognitive dysfunction is a fundamental -- yet frequently ignored or misidentified -- component of bipolar disorder. The first comprehensive book of its kind, Cognitive Dysfunction in Bipolar Disorder: A Guide for Clinicians compiles the latest data in neuropsychology, neuroimaging, neurogenetics, and functional outcomes research to enable clinicians to more effectively utilize pharmacological and psychotherapeutic techniques in their treatment of bipolar disorder.

This volume outlines and demystifies current knowledge about neuropsychological functioning in bipolar disorder in a reader-friendly, easy-to-understand guide for practitioners. Its 12 chapters, written by 23 internationally-renowned expert contributors, examine such topics as attentional and executive functioning, neuroimaging and genetic correlates of cognitive functioning, pharmacological strategies, bipolar disorder in pediatric patients, and cognition across the life span.

The book also comes with the added benefit of • A review of neurocognitive domains, examples of their operation in everyday life, the neuroanatomical regions with which they are associated, and common tests used to assess their function• Summarized data from large-scale clinical trials, including the National Institute of Mental Health Antipsychotic Trials of Intervention Effectiveness (CATIE) study• Take-home points at the end of each chapter summarizing main concepts and "clinical pearls"• Case studies and illustrative examples depicting the application of specific neurocognitive principles

Using relevant applications from cognitive neuroscience, Cognitive Dysfunction in Bipolar Disorder provides clinicians with a comprehensive overview of astounding breakthroughs in the assessment and treatment of patients with bipolar disorder. It plows new ground in the mental health industry, correcting distortions and laying the foundation for future clinical research in this rapidly expanding field.

Information about new psychotropic drugs, a summary of advances in knowledge about identifiable risk factors for adverse effects, and updated recommendations on viable "antidote" management strategies -- including novel pharmacotherapies for tardive dyskinesia and newer agents for weight loss -- are among the features of this new, second edition of Managing the Side Effects of Psychotropic Medications.

Where other psychopharmacology textbooks -- and, indeed, most internships and residencies in psychiatry -- lack a solid basis in primary care medicine, this guide bridges that educational gap, offering a thorough examination of all the effects of taking a psychotropic drug as well practical clinical advice on how to manage complications that arise.

The book is divided into three parts: The first deals with global issues that affect the assessment and formulation of possible adverse effects, as well as with pertinent concepts related to basic pharmacology, physiology, and medical monitoring. The second part presents information organized by individual organ systems or specific medical circumstances. The final part focuses on summary recommendations covering all the material presented in the book and is followed by helpful appendixes and self-assessment questions and resources for practitioners.

This new edition includes: • Updated summaries about what psychiatrists should know regarding drug-drug interactions, iatrogenic cardiac arrhythmias, drug pressor effects and orthostatic hypotension, and drug rashes; as well as updated discussions on avoiding lithium nephrotoxicity, handling adverse effect emergencies, and understanding new FDA classifications about drug safety during pregnancy• An expanded discussion on the strengths and limitations of pharmacogenetic testing to predict adverse drug effects, as well as information about new treatments for sexual dysfunction, sleep disturbances, cognitive complaints, and other maladies• Revised summary tables to aid rapid assessment and management• An expanded section on supplemental resources• An updated and expanded self-assessment section with more key questions

Busy clinicians will find in Managing the Side Effects of Psychotropic Medications an accessible reference that provides both scientific and scholarly discussion of the consequences of drug therapies they may prescribe (or avoid), the range of available strategies to effectively manage adverse effects, and the scientific and practical implications of their treatment decisions.

Aujourd'hui, la polypharmacologie est un outil majeur pour le traitement des patients souffrant de formes graves et chroniques de troubles de l'humeur, d'anxi�t�, de psychose ou de troubles du comportement.

Dans l'esprit des travaux et �crits de Stephen M. Stahl, cet ouvrage offre une vue d'ensemble novatrice sur les connaissances en psychopharmacologie et les strat�gies de prises de d�cision, en int�grant les r�sultats d'essais fond�s sur les preuves aux donn�es de la clinique, avec des exemples et des situations cliniques r�elles. Il aborde la mani�re dont les prescripteurs peuvent mettre en place une � psychopharmacologie sur mesure �, adapt�e aux besoins sp�cifiques de chaque patient, en conservant l'approche et l'�tat d'esprit d'un praticien.

Quelle que soit leur exp�rience, les professionnels pourront ainsi affiner et am�liorer leurs prescriptions et leurs prises en charge, en ciblant les manifestations des circuits neuronaux dysfonctionnels et les dimensions psychopathologiques, au-del� des diagnostics psychiatriques conventionnels.

Pr�sent� sous une forme dynamique, pratique et en couleurs, avec des tableaux de synth�se, des encadr�s et des vignettes cliniques concr�tes, cet ouvrage est un guide pr�cieux d'aide � la d�cision pour tous les praticiens qui prescrivent des psychotropes.

Joseph F. GoldbergProfesseur de psychiatrie clinique,Icahn School of Medicine at Mount Sinai, New York

Stephen M. StahlProfesseur de psychiatrie et de neurologie,University of California Riverside and University of California San Diego

Marc-Antoine Crocq (traducteur)Psychiatre,Maison des adolescents du Haut-Rhin, CAMUHA,Universit� de Haute-Alsace, Mulhouse